SpeeDx partners with Nepean Hospital to commercialise respiratory virus host biomarker assay
SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Nov 20
SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe
10 Nov 20
The partnership agreement, valued at more than $130m over the next five years, covers imaging technologies, digital solutions,…
10 Nov 20
Introducing a new portfolio of heart valve products aiming to restore health and extend life
10 Nov 20
Streamlining fabrication of dental products with LuxaDent 3D Printer and LuxDent software
10 Nov 20
ProTec Scientific Inc, officially launches ProTec 99, a new battery operated, hand held UV-C sterilization device, with a…
10 Nov 20
The company's FDA approved AI analysis algorithms will detect abnormalities in heart rhythm and structural heart disease
09 Nov 20
The trial will evaluate major adverse limb events in PAD patients with lesions below the inguinal ligament
09 Nov 20
Fujirebio will offer Lumipulse G SARS-CoV-2 Ag assay that can run on CLEIA-based Lumipulse G1200 instruments
08 Nov 20
Everlywell, a leading digital health company and provider of one of the only FDA-authorized at-home sample collection kits…
06 Nov 20
The project to validate the Empatica Covid-19 detection wearable technology will run parallel to an FDA submission for…